SCHEMBL3109917

SCHEMBL3109917

CCCN(Cc1nc(-c2ccc(Br)cc2)c(-c2ccc(Cl)cc2Cl)cc1CNC(=O)c1ccc(SC(F)(F)F)cc1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 4/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
NLRP1 Q9C000 1/20 0.36
KCNK2 O95069 4/20 0.36
KCNK10 P57789 4/20 0.36
PPARD Q03181 1/20 0.36
CNR1 P21554 3/20 0.34
EPHX2 P34913 2/20 0.34
NR1H4 Q96RI1 1/20 0.34
GCGR P47871 2/20 0.33
GCG P01275 1/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658814 0.86 KCNK2 (0.41) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3113811 0.86 KCNK2 (0.40) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3110314 0.86 DDR1 (0.38) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3115945 0.85 KCNK2 (0.39) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3102247 0.85 CNR1 (0.39) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3116597 0.85 KCNK2 (0.40) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3106166 0.85 DDR1 (0.36) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3105837 0.84 KCNK2 (0.38) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3103535 0.84 KCNK2 (0.39) DDR1LMNAMAPK1NLRP1KCNK2
SCHEMBL3113176 0.84 KCNK2 (0.36) DDR1LMNAMAPK1NLRP1KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362045-B2 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF ALK, ROS1, CYP11B2 DDR1 1315/4885LMNA 2880/4885MAPK1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.